Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ashford Hospitality Trust, Inc. and its officers or directors [1]. Group 1: Company Actions - On January 13, 2026, Ashford announced the extension of its Highland mortgage loan secured by 18 hotels and suspended preferred dividends to maintain liquidity while evaluating strategic alternatives [3]. - Following the announcement, Ashford's stock price decreased by $0.35 per share, or 8.1%, closing at $3.97 per share on the same day [3]. Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving First Citizens BancShares, Inc. and its officers or directors [1] Financial Performance - On January 23, 2026, First Citizens reported its fourth-quarter financial results for 2025, revealing an efficiency ratio of 64.5%, which missed analyst expectations and worsened compared to the previous year [3] - The company provided a weaker outlook, indicating expected deterioration in revenue and weak projections for net interest income in the upcoming year [3] Market Reaction - Following the financial results announcement, First Citizens' stock price dropped by $186.97 per share, or 8.49%, closing at $2,016.56 per share on January 23, 2026 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Pinterest, Inc. and its officers or directors, following a significant restructuring announcement by the company [1][3]. Group 1: Company Actions - On January 27, 2026, Pinterest announced a global restructuring plan that includes a workforce reduction affecting less than 15% of its employees and a reduction in office space [3]. - The company anticipates incurring pre-tax restructuring charges of approximately $35 million to $45 million, primarily in cash-related expenditures [3]. - The restructuring aims to support transformation initiatives focused on reallocating resources to AI roles, prioritizing AI-powered products, and accelerating changes in sales and marketing strategies [3]. Group 2: Market Reaction - Following the announcement of the restructuring plan, Pinterest's stock price fell by $2.49 per share, or 9.61%, closing at $23.41 per share on January 27, 2026 [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atlassian Corporation and its officers or directors [1]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Atlassian Corporation and is urging them to contact the firm for further information [1]. - The investigation focuses on whether Atlassian and its executives have engaged in any fraudulent activities [1]. Group 2: Stock Performance and Analyst Opinions - On January 16, 2026, Citi reduced its price target for Atlassian's stock from $240 to $210, citing concerns over the quality of revenue growth and the impact of code assistant platforms [3]. - Following the downgrade, Atlassian's stock price dropped by $9.90, or 7.71%, closing at $118.55 per share on the same day [3].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rambus Inc. (“Rambus” or the “Company”) (NASDAQ: RMBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Rambus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On February 2, 2026, Rambus reported its fourth quarter and fiscal year 2025 financi ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Patria Investments Limited and its officers or directors [1] Group 1: Investigation Details - Pomerantz LLP is representing investors of Patria Investments Limited and is urging them to contact the firm for further information [1] - The investigation is focused on whether Patria has engaged in securities fraud or other unlawful business practices [1] Group 2: Allegations and Market Reaction - On January 26, 2026, Snowcap Research published a report claiming that Patria may be overstating its performance and concealing losses in its private equity and infrastructure funds [3] - Following the release of this report, Patria's stock price decreased by $0.78 per share, representing a 4.55% decline, closing at $16.37 per share on the same day [3]

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pharming and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On February ...

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation, alleging securities fraud and unlawful business practices related to stock repurchases during a specific period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Masonite and its officers/directors engaged in securities fraud by failing to disclose multiple formal acquisition offers from Owens Corning while repurchasing its own stock at lower market prices [4]. - Investors who sold Masonite common stock during the Class Period have until April 7, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [5].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving RPC, Inc. and its officers or directors, following disappointing financial results that led to a significant drop in the company's stock price [1][3]. Financial Performance - On February 3, 2026, RPC reported its fourth quarter and full year 2025 financial results, revealing non-GAAP earnings per share of $0.04, which fell short of consensus estimates [3]. - The Support Services segment experienced an 18% sequential revenue decline, primarily due to a 22% drop in rental tools from Patterson Services during the quarter, attributed to several jobs being postponed to early 2026 [3]. - Following the financial report, RPC's stock price decreased by $1.15 per share, or 17.37%, closing at $5.47 per share on February 3, 2026 [3].